1359 studies found for:    Open Studies | "Leukemia"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Leukemia" (1359 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Lymphocytic Leukemia
Interventions: Drug: Lirilumab;   Drug: Rituximab
2 Recruiting Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Conditions: Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
Intervention:
3 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
4 Recruiting CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
Conditions: Acute Myeloid Leukemia;   Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;   T-cell Prolymphocytic Leukemia;   T-cell Large Granular Lymphocytic Leukemia;   Peripheral T-cell Lymphoma, NOS;   Angioimmunoblastic T-cell Lymphoma;   Extranodal NK/T-cell Lymphoma, Nasal Type;   Enteropathy-type Intestinal T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma
Intervention: Biological: anti-CD7 CAR-pNK cells
5 Not yet recruiting Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
6 Recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
7 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
8 Recruiting Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
9 Recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
10 Not yet recruiting Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Conditions: Acute Adult T-Cell Leukemia/Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Chronic Adult T-Cell Leukemia/Lymphoma;   HTLV-1 Infection;   Lymphomatous Adult T-Cell Leukemia/Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Smoldering Adult T-Cell Leukemia/Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacogenomic Study
11 Not yet recruiting Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Intervention: Drug: Ex vivo-expanded autologous T cells modified to express CD19 CAR
12 Unknown  Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
13 Recruiting Study of the Glutaminase Inhibitor CB-839 in Leukemia
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL)
Interventions: Drug: CB-839;   Drug: CB-Aza
14 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Acute Biphenotypic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
15 Recruiting PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia
Intervention: Drug: MT-3724
16 Recruiting Ruxolitinib for Adult T-Cell Leukemia
Conditions: T Cell Leukemia, Adult;   Leukemia, Adult T-Cell;   T Cell Leukemia, HTLV I Associated
Intervention: Drug: Ruxolitinib
17 Recruiting Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: ofatumumab;   Procedure: biopsy
18 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia;   Lymphoplasmacytic Lymphoma;   Waldenstrom Macroglobulinemia;   Splenic Marginal Zone Lymphoma
Intervention:
19 Recruiting Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
20 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years